Eunpi Cho1, Ann K Schwemm2, Lena M Rubinstein3, Philip A Stevenson4, Ted A Gooley5, Georgiana K Ellis1, Jennifer M Specht1, Robert B Livingston6, Hannah M Linden1, Vijayakrishna K Gadi7. 1. Department of Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. 2. Department of Pharmacology, University of Washington, Seattle, WA. 3. Department of Medicine, University of Washington, Seattle, WA. 4. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA. 5. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Public Health Services Division, Fred Hutchinson Cancer Research Center, Seattle, WA. 6. University of Arizona College of Medicine, Tucson, AZ. 7. Department of Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Public Health Services Division, Fred Hutchinson Cancer Research Center, Seattle, WA. Electronic address: vkgadi@u.washington.edu.
Abstract
BACKGROUND: Commonly used adjuvant systemic therapies harbor high rates of severe short-term and long-term side effects but are often justified to patients because of curative intent in early-stage breast cancer. One of the oldest and least toxic adjuvant regimens, CMF (oral cyclophosphamide given with intravenous methotrexate and 5-fluorouracil), has been largely abandoned because of the perception that it underperforms for survival outcomes compared with modern regimens containing anthracycline and/or taxanes. MATERIALS AND METHODS: To address this misperception, we performed a review of all consecutive breast cancer patients at the Seattle Cancer Care Alliance over the past decade who received 6 months of adjuvant CMF as their sole chemotherapy regimen and determined rates for relapse-free survival (RFS), overall survival (OS), and major organ toxicity. From January 2003 to August 2013, 248 patients (median age of 52 years at the start of chemotherapy) met criteria for inclusion in this series and had a median follow-up of 67 months. RESULTS: RFS and OS at 5 years was 94.5% (91.3%-97.9%) and 98% (96%-100%), respectively. The only major organ toxicity that occurred in > 5% of patients was Grade 3 neutropenia (18.1%, 24 patients). One patient died during therapy from pneumocystis pneumonia attributed to previously undiagnosed AIDS. CONCLUSION: In a modern cohort of patients thoroughly characterized for Grade and hormone receptor status, CMF was a well-tolerated and effective adjuvant regimen for early-stage breast cancer and should be considered for appropriately selected patients.
BACKGROUND: Commonly used adjuvant systemic therapies harbor high rates of severe short-term and long-term side effects but are often justified to patients because of curative intent in early-stage breast cancer. One of the oldest and least toxic adjuvant regimens, CMF (oral cyclophosphamide given with intravenous methotrexate and 5-fluorouracil), has been largely abandoned because of the perception that it underperforms for survival outcomes compared with modern regimens containing anthracycline and/or taxanes. MATERIALS AND METHODS: To address this misperception, we performed a review of all consecutive breast cancerpatients at the Seattle Cancer Care Alliance over the past decade who received 6 months of adjuvant CMF as their sole chemotherapy regimen and determined rates for relapse-free survival (RFS), overall survival (OS), and major organ toxicity. From January 2003 to August 2013, 248 patients (median age of 52 years at the start of chemotherapy) met criteria for inclusion in this series and had a median follow-up of 67 months. RESULTS: RFS and OS at 5 years was 94.5% (91.3%-97.9%) and 98% (96%-100%), respectively. The only major organ toxicity that occurred in > 5% of patients was Grade 3 neutropenia (18.1%, 24 patients). One patient died during therapy from pneumocystis pneumonia attributed to previously undiagnosed AIDS. CONCLUSION: In a modern cohort of patients thoroughly characterized for Grade and hormone receptor status, CMF was a well-tolerated and effective adjuvant regimen for early-stage breast cancer and should be considered for appropriately selected patients.
Authors: Stephen E Jones; Michael A Savin; Frankie Ann Holmes; Joyce A O'Shaughnessy; Joanne L Blum; Svetislava Vukelja; Kristi J McIntyre; John E Pippen; James H Bordelon; Robert Kirby; John Sandbach; William J Hyman; Pankaj Khandelwal; Angel G Negron; Donald A Richards; Stephen P Anthony; Robert G Mennel; Kristi A Boehm; Walter G Meyer; Lina Asmar Journal: J Clin Oncol Date: 2006-12-01 Impact factor: 44.544
Authors: Kathleen I Pritchard; Lois E Shepherd; Frances P O'Malley; Irene L Andrulis; Dongsheng Tu; Vivien H Bramwell; Mark N Levine Journal: N Engl J Med Date: 2006-05-18 Impact factor: 91.245
Authors: Maggie C U Cheang; K David Voduc; Dongsheng Tu; Shan Jiang; Samuel Leung; Stephen K Chia; Lois E Shepherd; Mark N Levine; Kathleen I Pritchard; Sherri Davies; Inge J Stijleman; Carole Davis; Mark T W Ebbert; Joel S Parker; Matthew J Ellis; Philip S Bernard; Charles M Perou; Torsten O Nielsen Journal: Clin Cancer Res Date: 2012-02-20 Impact factor: 12.531
Authors: Prudence Francis; John Crown; Angelo Di Leo; Marc Buyse; Ana Balil; Michael Andersson; Bo Nordenskjöld; Istvan Lang; Raimund Jakesz; Daniel Vorobiof; Jorge Gutiérrez; Guy van Hazel; Stella Dolci; Sophie Jamin; Belguendouz Bendahmane; Richard D Gelber; Aron Goldhirsch; Monica Castiglione-Gertsch; Martine Piccart-Gebhart Journal: J Natl Cancer Inst Date: 2008-01-08 Impact factor: 13.506
Authors: Sandra M Swain; Jong-Hyeon Jeong; Charles E Geyer; Joseph P Costantino; Eduardo R Pajon; Louis Fehrenbacher; James N Atkins; Jonathan Polikoff; Victor G Vogel; John K Erban; Priya Rastogi; Robert B Livingston; Edith A Perez; Eleftherios P Mamounas; Stephanie R Land; Patricia A Ganz; Norman Wolmark Journal: N Engl J Med Date: 2010-06-03 Impact factor: 176.079
Authors: R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard Journal: Lancet Date: 2011-12-05 Impact factor: 79.321